Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity

Overview of attention for article published in International Journal of Retina and Vitreous , October 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis

Article in Survey of Ophthalmology (March 2024)

Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis

Article in Biomolecules and Biomedicine (November 2023)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis

Article in Italian Journal of Pediatrics (October 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.